Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin

R. D. Snyder; G. N. Hortobagyi; G. P. Bodey; J. U. Gutterman; E. M. Hersh

doi:10.1002/jso.2930160113

Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin

R. D. Snyder, G. N. Hortobagyi, G. P. Bodey, J. U. Gutterman, E. M. Hersh

Research output: Contribution to journal › Article › peer-review

Abstract

A study was undertaken to investigate the addition of heparin and pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front‐line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of pseudomonas vaccine that seemed to be tolerated has been established.

Original language	English (US)
Pages (from-to)	87-92
Number of pages	6
Journal	Journal of Surgical Oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1002/jso.2930160113
State	Published - 1981
Externally published	Yes

Keywords

BCNU
anticoagulation in melanoma

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.2930160113

Cite this

@article{916d2ce623fd43f5b994aa38b1a55e38,

title = "Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin",

abstract = "A study was undertaken to investigate the addition of heparin and pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front‐line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of pseudomonas vaccine that seemed to be tolerated has been established.",

keywords = "BCNU, anticoagulation in melanoma",

author = "Snyder, {R. D.} and Hortobagyi, {G. N.} and Bodey, {G. P.} and Gutterman, {J. U.} and Hersh, {E. M.}",

year = "1981",

doi = "10.1002/jso.2930160113",

language = "English (US)",

volume = "16",

pages = "87--92",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin

AU - Snyder, R. D.

AU - Hortobagyi, G. N.

AU - Bodey, G. P.

AU - Gutterman, J. U.

AU - Hersh, E. M.

PY - 1981

Y1 - 1981

N2 - A study was undertaken to investigate the addition of heparin and pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front‐line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of pseudomonas vaccine that seemed to be tolerated has been established.

AB - A study was undertaken to investigate the addition of heparin and pseudomonas vaccine to BCNU in the treatment of patients with progressive malignant melanoma refractory to front‐line therapeutic regimens containing DTIC. Out of 27 evaluable patients, there was one partial remission (4%), and an additional ten patients (41%) had at least stable disease with a median survival time of 39 weeks compared to 15 weeks for those with progressive disease. The therapy was well tolerated. A schedule of pseudomonas vaccine that seemed to be tolerated has been established.

KW - BCNU

KW - anticoagulation in melanoma

UR - http://www.scopus.com/inward/record.url?scp=0019366822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019366822&partnerID=8YFLogxK

U2 - 10.1002/jso.2930160113

DO - 10.1002/jso.2930160113

M3 - Article

C2 - 7464150

AN - SCOPUS:0019366822

SN - 0022-4790

VL - 16

SP - 87

EP - 92

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 1

ER -

Combination therapy for advanced malignant melanoma with BCNU, pseudomonas vaccine, and heparin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this